LymeNet Home LymeNet Home Page LymeNet Flash Discussion LymeNet Support Group Database LymeNet Literature Library LymeNet Legal Resources LymeNet Medical & Scientific Abstract Database LymeNet Newsletter Home Page LymeNet Recommended Books LymeNet Tick Pictures Search The LymeNet Site LymeNet Links LymeNet Frequently Asked Questions About The Lyme Disease Network LymeNet Menu

LymeNet on Facebook

LymeNet on Twitter




The Lyme Disease Network receives a commission from Amazon.com for each purchase originating from this site.

When purchasing from Amazon.com, please
click here first.

Thank you.

LymeNet Flash Discussion
Dedicated to the Bachmann Family

LymeNet needs your help:
LymeNet 2020 fund drive


The Lyme Disease Network is a non-profit organization funded by individual donations.

LymeNet Flash Post New Topic  New Poll  Post A Reply
my profile | directory login | register | search | faq | forum home

  next oldest topic   next newest topic
» LymeNet Flash » Questions and Discussion » Medical Questions » FYI - Cefazolin recall

 - UBBFriend: Email this page to someone!    
Author Topic: FYI - Cefazolin recall
DocLand
Member
Member # 7794

Icon 1 posted      Profile for DocLand     Send New Private Message       Edit/Delete Post   Reply With Quote 
MedWatch - The FDA Safety Information and Adverse Event Reporting Program

Hanford Pharmaceuticals and FDA notified healthcare professionals about the
recall of four lots (379,975 vials) of Cefazolin for Injection, USP, 1 g/10
mL vials, an antibiotic used in a hospital environment to treat skin and
skin structure, respiratory and other infections.The product was distributed
by Sandoz, Inc. of Broomfield, CO and Watson Pharmaceuticals, Inc. of
Corona, CA. Certain lots of the active ingredient used to manufacture the
product have been shown to contain microbial contamination (Bacillus
pumilus, Staphylococcus hominis, Propionibacterium acnes, or Micrococcus
luteus) which may pose a serious or life-threatening risk for some patients.
Hospitals, clinics, and users should stop using the affected lots
immediately.

Read the complete MedWatch 2006 Safety summary, including a link to the
firm's press release, at:

http://www.fda.gov/medwatch/safety/2006/safety06.htm#Cefazolin

_________________________________________________________________

Thank you for using MedWatch as a trusted source for timely safety information
on drugs and other medical products regulated by the U.S. Food and Drug
Administration. If you find this e-mail notification helpful, please consider
telling colleagues and friends about MedWatch. They can learn more about us
and subscribe/unsubscribe to the e-list at the MedWatch homepage,
http://www.fda.gov/medwatch or by going directly to
https://list.nih.gov/cgi-bin/wa?SUBED1=medwatch&A=1


This is an automated message delivery system -- replying to this message
will not reach MedWatch staff. If you have comments or questions about
MedWatch or this e-mail, please contact us through our comments & feedback
web page, http://www.fda.gov/medwatch/feedback.htm

Posts: 31 | From Arlington, VA USA | Registered: Aug 2005  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code� is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | LymeNet home page | Privacy Statement

Powered by UBB.classic™ 6.7.3


The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:

The Lyme Disease Network of New Jersey
907 Pebble Creek Court, Pennington, NJ 08534 USA


| Flash Discussion | Support Groups | On-Line Library
Legal Resources | Medical Abstracts | Newsletter | Books
Pictures | Site Search | Links | Help/Questions
About LymeNet | Contact Us

© 1993-2020 The Lyme Disease Network of New Jersey, Inc.
All Rights Reserved.
Use of the LymeNet Site is subject to Terms and Conditions.